TUESDAY, JUNE 19, 2018

Australia grants Zoetis' new Hendra virus vaccine full registration

Australia grants Zoetis' new Hendra virus vaccine full registration.
Australia grants Zoetis' new Hendra virus vaccine full registration. | Courtesy of medicalexpo.com
Zoetis recently announced that the Australia Pesticides and Veterinary Medicines Authority (APVMA) has granted full registration for Equivac HeV, a vaccine for the Hendra virus.

“As a veterinarian, I have seen the devastating consequences of Hendra virus first hand,” Tablelands Veterinary Clinic's Dr. Frank Condon said. “This case could have been far worse if all nine horses were not vaccinated. You simply can’t take chances with this deadly disease.”

In light of increasing outbreaks and horse deaths throughout New South Wales and Queensland, scientists designed Equivac HeV in Nov. 2012.

“The Hendra vaccine has always been deemed safe by the regulator,” Condon said. “Horse owners and vets should take comfort in knowing that this vaccine has met the necessary requirements for registration.”

There has been a second outbreak in 2015, and the fully registration was granted one week later.

“The time to vaccinate is now,” Condon said. “I urge all horse owners to protect their horses, friends and family by vaccinating and remaining compliant with boosters.”

This marks an exciting time for veterinary research.

“We at Zoetis are pleased that after nearly three years of positive uptake, Equivac HeV vaccine has successfully been registered,” Lance Williams, general manager for Zoetis in Australia and New Zealand, said. “The APVMA undertakes one of the most detailed assessment processes in the world before approving registration of a product and Equivac HeV passed every assessment criteria for registration. Equivac HeV demonstrates Zoetis’ commitment to providing horse owners with quality animal health solutions they can count on.”

Organizations in this Story

Zoetis Inc

Want to get notified whenever we write about Zoetis Inc ?
Next time we write about Zoetis Inc, we'll email you a link to the story. You may edit your settings or unsubscribe at any time.